业界动态国内医卫资讯
STAT+:医生们对Watchman有疑问。波士顿科学公司有一套推销说辞。
STAT News · 2026-11-14 01:55
摘要
尽管遭遇了种种挫折,波士顿科学公司不会停止推销Watchman。这家医疗器械巨头十多年前投入数亿美元收购了这款微型心脏植入物,随后在食品药品监督管理局(FDA)经历了长达数年的关于是否批准它的争论。当批准最终获批、且仅针对有限的患者群体时,波士顿科学公司已经准备好了一项针对更大市场的计划。继续阅读STAT+以了解完整报道……
English
STAT+: Doctors have questions about the Watchman. Boston Scientific has a sales pitch.
Despite all the setbacks, Boston Scientific won’t stop pushing the Watchman. The medical-device giant committed hundreds of millions to acquire the tiny heart implant more than a decade ago, and then endured a years-long debate at the Food and Drug Administration over whether to approve it. When that approval finally came through, for a limited pool of patients, Boston Scientific was prepared with a plan for something much larger. Continue to STAT+ to read the full story…